Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics on Emergence of Functional Gastrointestinal Disorders, Body Composition, Mineral Bone Density and Fecal Microbiota in Infancy

Trial Profile

Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics on Emergence of Functional Gastrointestinal Disorders, Body Composition, Mineral Bone Density and Fecal Microbiota in Infancy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Lactobacillus reuteri (Primary) ; Ampicillin; Gentamicin
  • Indications Gastrointestinal disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top